Modulation of human dendritic cell phenotype and function by probiotic bacteria

A L Hart, K Lammers, P Brigidi, B Vitali, F Rizzello, P Gionchetti, M Campieri, M A Kamm, S C Knight, A J Stagg


Background: “Probiotic” bacteria are effective in treating some inflammatory bowel diseases. However, which bacteria confer benefit and mechanisms of action remain poorly defined. Dendritic cells, which are pivotal in early bacterial recognition, tolerance induction, and shaping of T cell responses, may be central in mediating the effects of these bacteria.

Aims: To assess effects of different probiotic bacteria on dendritic cell function.

Methods: Human intestinal lamina propria mononuclear cells, whole blood, or an enriched blood dendritic cell population were cultured with cell wall components of the eight bacterial strains in the probiotic preparation VSL#3 (four lactobacilli, three bifidobacteria, and one streptococcal strains). Dendritic cells were identified and changes in dendritic cell maturation/costimulatory markers and cytokine production in response to probiotic bacteria were analysed by multicolour flow cytometry, in addition to subsequent effects on T cell polarisation.

Results: VSL#3 was a potent inducer of IL-10 by dendritic cells from blood and intestinal tissue, and inhibited generation of Th1 cells. Individual strains within VSL#3 displayed distinct immunomodulatory effects on dendritic cells; the most marked anti-inflammatory effects were produced by bifidobacteria strains which upregulated IL-10 production by dendritic cells, decreased expression of the costimulatory molecule CD80, and decreased interferon-γ production by T cells. VSL#3 diminished proinflammatory effects of LPS by decreasing LPS induced production of IL-12 while maintaining IL-10 production.

Conclusions: Probiotic bacteria differ in their immunomodulatory activity and influence polarisation of immune responses at the earliest stage of antigen presentation by dendritic cells.

The intestinal immune system forms the largest part of the immune system. It interacts with a complex antigenic load in the form of food antigens, commensal bacteria, and occasional pathogens. Dendritic cells (DC) are pivotal in earliest bacterial recognition and in shaping T cell responses. In the intestine DC have specialised functions most likely as a result of their close proximity with the external environment. They are involved in generating regulatory T cells and IgA producing B cells through production of cytokines such as IL-10 and TGFβ. They contribute to oral tolerance induction and determine homing of lymphocytes back into intestinal tissue. Intestinal DC interact directly with luminal bacteria by passing their dendrites between epithelial tight junctions into the gut lumen and indirectly with bacteria that have gained access via M cells.

Microbial products play a key role in regulating DC responses. DC interact with microbes using pattern recognition receptors, including toll-like receptors (TLR). Using such a system, DC distinguish between and mount different responses to recently evolved unrelated organisms. For example, lipopolysaccharide (LPS) from E coli interacts with TLR4 and generates a Th1 response, whereas LPS from Porphyromonas gingivalis interacts with TLR2 and generates a Th2 response. This ability to respond appropriately to different microbial products is of particular importance in the gastrointestinal tract, where a diverse microbial flora lies close to DC.

Dendritic cells sense antigen in tissues before migrating to draining lymph nodes, where they have the unique ability to activate and influence functional differentiation of naïve T cells. Signals from DC can determine whether tolerance or an active immune response occurs to a particular antigen and furthermore influence whether a Th1 or Th2 immune response predominates. DC subtype, whether CD11c+ (myeloid) or CD11c− (plasmacytoid/lymphoid), maturation status, and cytokine production contribute to the type of T cell response. For example, DC upregulate the costimulatory molecules, CD80 and CD86, and produce IL-12 which contributes to a Th1 response. DC also produce IL-10 and IL-4 which promote the generation of a Th2 response or regulatory T cells.

Some commensal organisms from intestinal flora have health-promoting properties and are used in probiotic preparations. The probiotic mixture, VSL#3 (VSL#3 Pharmaceuticals, Fort Lauderdale, FL, USA), which contains eight different bacterial strains (four lactobacilli, three bifidobacteria, and one Streptococcus thermophilus subsp Salivarus) is beneficial in treating some inflammatory bowel diseases (IBD). Controlled clinical trials have shown that VSL#3 maintains remission of pouchitis and prevents onset of pouchitis after pouch formation. The non-pathogenic E coli Nissle strain is beneficial in maintenance treatment of ulcerative colitis.

Central to the mechanism of action of probiotics is the modulation of host immune response. An increased understanding of the effects of clinically active probiotic bacteria on the immune system may enable refinement of probiotic treatments for use under defined disease circumstances and enhance our knowledge of immune homeostasis in the gastrointestinal tract.

Abbreviations: DC, dendritic cell; ELISA, enzyme linked immunosorbent assay; IBD, inflammatory bowel diseases; LPDC, lamina propria DC; LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cell; PE, phycoerythrin; TLR, toll-like receptor.
specialised environment of the intestine. We hypothesised that probiotic organisms exert modulatory activity on the host immune system via DC. The objective was to investigate effects of combined and individual probiotic strains and LPS on the phenotype and function of both blood and intestinal DC derived from the colonic lamina propria in order to establish which organisms may confer benefits at this early stage in antigen presentation. Cross regulatory effects between microbial products inducing polarised responses were also assessed. Furthermore, the subsequent effect of DC exposed to probiotic bacteria on polarisation of the T cell response was examined.

METHODS
Preparation of bacterial fractions
The bacterial fractions investigated are shown in table 1. Bacterial fractions were prepared as described in Lammers, et al.21 The VSL#3 Lactobacillus and Bifidobacterium strains were grown anaerobically at 37°C in MR5 medium (Difco, USA) supplemented with 0.05% L-cysteine. The VSL#3 Streptococcus salivarius subsp thermophilus was grown anaerobically in M17 medium (Difco, USA). Streptococcus faecium was also grown anaerobically in M17 medium. Non-pathogenic Escherichia coli Nissle strain 1917 was grown aerobically in LB (Difco, USA). Mid log cultures were collected by centrifugation and subsequently sonicated (Branson Sonifier W-250, Heinemann, Schwäbisch, Germany) at a power level 5–6 at 30% duty for five minutes. Sonicates were centrifuged and bacterial debris fractions were collected. In assays where all strains were assessed in combination, sonicates of individual strains were pooled.

Monoclonal antibodies
The antibodies used were: CD11c-FITC (KB90) (Dako, Cambridgeshire, UK); CD3-PC5 (UCHT-1), CD14-PC5 (M199), CD16-PE (B73.1), CD19-PC5 (4G7), CD56-PC5 (N901), and CD8-PC5 (B9.11) (Beckman Coulter, High Wycombe, UK); CD34-CyChrome (581), CD86-PE (BU63), CD3-PC5 (UCHT-1), CD69-PE (FN50), and CD8-FITC/PE/APC (SK1) (BD Biosciences Pharmingen, Oxford, UK). Isotype controls were matched obtained from the same manufacturers. Intracellular cytokine staining used: IFN-γ-PE (clone D9D10), IFN-γ-FITC (clone B-B1), IL-10-PE (clone JES3-9D7) (Serotec, Oxford, UK), and IL-12(p40)-PE (clone C11.5) and IL-4-PE (3007.11) (BD Biosciences Pharmingen, UK). Neutralising anti-IL-10 antibody (Clone 9D7) was purchased from Endogen (Cheshire, UK).

Bacterial strains
Bacterial strains were grown anaerobically at 37°C in MRS medium (Difco, USA) supplemented with 0.05% L-cysteine. The VSL#3 Lactobacillus and Bifidobacterium strains were grown anaerobically at 37°C in MR5 medium (Difco, USA) supplemented with 0.05% L-cysteine. The VSL#3 Streptococcus salivarius subsp thermophilus was grown anaerobically in M17 medium (Difco, USA). Streptococcus faecium was also grown anaerobically in M17 medium. Non-pathogenic Escherichia coli Nissle strain 1917 was grown aerobically in LB (Difco, USA). Mid log cultures were collected by centrifugation and subsequently sonicated (Branson Sonifier W-250, Heinemann, Schwäbisch, Germany) at a power level 5–6 at 30% duty for five minutes. Sonicates were centrifuged and bacterial debris fractions were collected. In assays where all strains were assessed in combination, sonicates of individual strains were pooled.

Table 1  Bacterial strains

<table>
<thead>
<tr>
<th>Bacterial strains</th>
<th>VSL#3 Tobaccoa, Goathurst, MD, USA</th>
<th>VSL#3 Tobaccoa, Goathurst, MD, USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactobacillus acidophilus MB443</td>
<td>Lactobacillus acidophilus MB443</td>
<td></td>
</tr>
<tr>
<td>Lactobacillus delbrueckii subsp. bulgaricus MB 453</td>
<td>Lactobacillus delbrueckii subsp. bulgaricus MB 453</td>
<td></td>
</tr>
<tr>
<td>Lactobacillus casei MB 451</td>
<td>Lactobacillus casei MB 451</td>
<td></td>
</tr>
<tr>
<td>Lactobacillus plantarum MB452</td>
<td>Lactobacillus plantarum MB452</td>
<td></td>
</tr>
<tr>
<td>Bifidobacterium longum Y10</td>
<td>Bifidobacterium longum Y10</td>
<td></td>
</tr>
<tr>
<td>Bifidobacterium infantis Y1</td>
<td>Bifidobacterium infantis Y1</td>
<td></td>
</tr>
<tr>
<td>Bifidobacterium breve Y8</td>
<td>Bifidobacterium breve Y8</td>
<td></td>
</tr>
<tr>
<td>Streptococcus salivarius subsp. thermophilus MB455</td>
<td>Streptococcus salivarius subsp. thermophilus MB455</td>
<td></td>
</tr>
<tr>
<td>Other bacterial strains used</td>
<td>Other bacterial strains used</td>
<td></td>
</tr>
<tr>
<td>Escherichia coli non-pathogenic Nissle strain 1917 (Mutafior-Argdeymph. Herdecke, Germany)</td>
<td>Escherichia coli non-pathogenic Nissle strain 1917 (Mutafior-Argdeymph. Herdecke, Germany)</td>
<td></td>
</tr>
<tr>
<td>Lipopolysaccharide from E coli 026:B6</td>
<td>Lipopolysaccharide from E coli 026:B6</td>
<td></td>
</tr>
<tr>
<td>Streptococcus faecium MB454</td>
<td>Streptococcus faecium MB454</td>
<td></td>
</tr>
</tbody>
</table>

Blood dendritic cells
Blood was collected from healthy volunteers into lithium heparin and incubated with culture medium alone (RPMI-1640 Dutch Modification, Sigma-Aldrich, UK), varying concentrations of bacterial cell debris fractions (10−6 to 109 CFU/ml), LPS (1 µg/ml) or control medium alone for four or 16 hours at 37°C in 5% CO2. An enriched DC population was prepared from peripheral blood mononuclear cells (PBMC). PBMC were prepared by centrifugation of blood over a Ficoll-Paque gradient (Amersham Biosciences) and cultured overnight in complete medium (RPMI-1640 Dutch Modification supplemented with 10% FCS, 2 mM L-glutamine, 100 µg/ml streptomycin, 100 U/ml penicillin) at 37°C in 5% CO2. Non-adherent DC rich low density cells were separated on hypertonic metrizamide (14.5% w/v) by centrifugation and incubated at 37°C in 5% CO2 for four hours with bacterial cell debris fractions, LPS or control medium alone.

Human colonic lamina propria dendritic cells
Human intestinal biopsies were obtained at routine colonoscopy from patients with macroscopically and histologically normal intestine who had been referred with rectal bleeding or altered bowel habit. Informed consent was obtained and the protocol was approved by the local ethics committee. At least 10 mucosal biopsies (approximately 60 mg) were taken per patient.22 Collagenase digestion of tissue was performed using collagenase D (Roche Diagnostics, Mannheim, Germany) in 10 ml RPMI-1640 HEPES (Sigma Aldrich Co Ltd, Irvine, UK), 2% FCS and 2 µM DNase I (Boehringer, Mannheim, Germany). Lamina propria mononuclear cells (2.5×105 cells per well, Falcon 96 well, U bottom) were cultured for four hours at 37°C in 5% CO2 with bacterial cell debris fractions, LPS, or control medium alone.

Cytokine production by DC
Cytokine production by DC subsets was assessed by intracellular staining in whole blood cultures, enriched DC cultures, and intestinal cell cultures in a modification of the method described by North et al.23 Comparison of paired cultures, one incubated with monensin (3 µmol/l) to maintain cytokine within the cells and the other incubated without monensin allowed assessment of cytokine production. In whole blood assays, red cells were lysed with 500 µl Optilyse C (Beckman Coulter, High Wycombe, UK) for 15 minutes at room temperature. Cells were fixed with Leucoperm A (100 µl, Serotec) and permeabilised with Leucoperm B (100 µl, Serotec). The cytokine antibody (5 µl) was added for 30 minutes. Blocking experiments were performed with an unlabelled antibody of an identical clone to the one used for cytokine staining and an irrelevant antibody to assess specificity of binding.

Enzyme linked immunosorbent assay (ELISA)
Concentrations of IL-10 in culture supernatants from enriched DC populations incubated with bacterial fractions were measured by ELISA using a paired antibody kit (Endogen, UK). IL-10 coating antibody was used at 2 µg/ml and biotinylated antihuman IL-10 detecting antibody at 0.75 µg/ml. Absorbance values were read at 450 nm on an ELISA plate reader. The assay’s detection limit was 36 pg IL-10/ml.

Differentiation of T cells after exposure to bacterial products
Two methods were used to assess effects of exposure to bacterial products on the subsequent T cell response. Naïve CD4⁺ T cells were prepared from PBMC by negative selection to a purity >87% using a StemSep kit (StemCell Technologies).
DC rich low density cells (8×10^3 cells per well) exposed to control medium alone, VSL#3 (10^8 CFU/ml) or LPS (1 μg/ml) were co-cultured with 4×10^5 per well allogeneic naïve CD4+ T cells for six days. This time point, cultures were supplemented with 30 U/ml recombinant IL-2. After a further six days, cells were cultured for four hours in complete medium with phorbol-myristate-acetate (PMA; 16.2 μmol/l), ionomycin (2 μmol/l), and monensin (3 μmol/l) or monensin alone. Cytokine production was assessed by intracellular staining.

To assess whether prior exposure to bacterial products influences IFN-γ production by polyclonally activated T cells, blood was incubated with varying concentrations of bacterial fractions in culture medium for 14 hours at 37°C in 5% CO2. To assess the role of IL-10, a neutralising anti-IL-10 antibody or an isotype matched control antibody was added to some cultures (20 μg/ml). Subsequently, cultures were activated with phorbol-myristate-acetate (PMA) and ionomycin, in addition to monensin, or treated with monensin alone for a further four hours at 37°C in 5% CO2. Cytokine production was assessed by intracellular staining.

Data and statistical analysis

Data were acquired uncompensated using a FACS Calibur (Becton Dickinson) flow cytometer. Objective compensation was applied using the Compensation Toolbox within the WinList Version 5.0 flow cytometry software (Verity, Topsham, ME USA). The proportion of cytokine positive cells was determined by subtraction of histograms using the super-enhanced Dmax (SED) normalised subtraction facility in WinList. Staining of cells cultured in the absence of monensin was subtracted from staining of cells cultured in the presence of monensin, giving a measure of ongoing cytokine production. This technique allows positive cells to be resolved in situations where distribution histograms overlap. The use of the same antibody to label cells from
Probiotic bacteria modulate dendritic cell function

Both monensin treated and untreated cultures gives this technique a high degree of sensitivity for detecting small changes in antibody binding. Specificity of antibody labelling was confirmed in competition experiments with unlabelled antibodies. Absolute cell counts were obtained by reference to counts of Flow-Count fluorospheres acquired simultaneously. Two tailed \( t \) tests were used to compare proportions and absolute numbers of cells. Data were paired where appropriate. Values of \( p<0.05 \) were regarded as significant.

RESULTS

Identification of dendritic cells

Blood DC were identified as HLA-DR+ lineage negative (CD3–, CD14–, CD16–, CD19–, CD34–, CD56–) cells. Within this gate, CD11c+ (myeloid) and CD11c– (plasmacytoid) DC populations were present. Cytokine production by CD11c+ and CD11c– DC populations was assessed by intracellular staining. Cytokine detection was competitively inhibited by unlabelled antibody of the same clone as that used for cytokine detection, but not by unlabelled antibody of irrelevant specificity (fig 1).

VSL\#3 upregulates IL-10 and downregulates IL-12 production by blood and colonic lamina propria dendritic cells

The probiotic combination VSL\#3 at a dose equivalent to \( 10^8 \) CFU/ml upregulated IL-10 production and decreased IL-12 production by CD11c+ and CD11c– DC (fig 2). This increase in IL-10 production in the presence of VSL\#3 was comparable in monensin treated and untreated cultures gives this technique a high degree of sensitivity for detecting small changes in antibody binding. Specificity of antibody labelling was confirmed in competition experiments with unlabelled antibodies. Absolute cell counts were obtained by reference to counts of Flow-Count fluorospheres acquired simultaneously. Two tailed \( t \) tests were used to compare proportions and absolute numbers of cells. Data were paired where appropriate. Values of \( p<0.05 \) were regarded as significant.

RESULTS

Identification of dendritic cells

Blood DC were identified as HLA-DR+ lineage negative (CD3–, CD14–, CD16–, CD19–, CD34–, CD56–) cells. Within this gate, CD11c+ (myeloid) and CD11c– (plasmacytoid) DC populations were present. Cytokine production by CD11c+ and CD11c– DC populations was assessed by intracellular staining. Cytokine detection was competitively inhibited by unlabelled antibody of the same clone as that used for cytokine detection, but not by unlabelled antibody of irrelevant specificity (fig 1).

VSL\#3 upregulates IL-10 and downregulates IL-12 production by blood and colonic lamina propria dendritic cells

The probiotic combination VSL\#3 at a dose equivalent to \( 10^8 \) CFU/ml upregulated IL-10 production and decreased IL-12 production by CD11c+ and CD11c– DC (fig 2). This increase in IL-10 production in the presence of VSL\#3 was comparable in monensin treated and untreated cultures gives this technique a high degree of sensitivity for detecting small changes in antibody binding. Specificity of antibody labelling was confirmed in competition experiments with unlabelled antibodies. Absolute cell counts were obtained by reference to counts of Flow-Count fluorospheres acquired simultaneously. Two tailed \( t \) tests were used to compare proportions and absolute numbers of cells. Data were paired where appropriate. Values of \( p<0.05 \) were regarded as significant.
Individual bacterial strains differentially modulate IL-10 and IL-12 production and expression of costimulatory/maturation markers by dendritic cells

Different bacterial strains evoked different cytokine responses when cultured with whole blood (fig 6). All bifidobacteria significantly upregulated IL-10 production by both CD11c+ and CD11c− DC and this increase in IL-10 was dose dependent over the range of concentrations 10⁵–10⁷ CFU/ml (data not shown). In contrast, lactobacilli decreased or had no significant effect on production of IL-10 by both CD11c+ and CD11c− DC. Streptococcal strains had no significant effect on IL-10-producing DC.

None of the bacteria tested induced IL-12 production by CD11c+ or CD11c− DC. Some components of VSL#3, illustrated in figure 6, significantly inhibited IL-12 production.

VSL#3 strains differentially modulated DC expression of maturation and costimulatory molecules (table 2). The proportion of DC expressing CD80 was significantly less in cultures stimulated with the bifidobacteria strains than in unstimulated cultures: B infantis and B breve affected both CD11c+ and CD11c− DC; only CD11c− DC were significantly affected by B longum. In unstimulated cultures the majority of DC expressed CD40. None of the bacterial preparations significantly altered the proportion of CD40+ DC although there was a trend towards a reduction in cultures stimulated with bifidobacteria. Consistent with an effect of bifidobacteria on CD40 expression, analysis of the level of CD40 expression demonstrated a significantly lower level of CD40 on CD11c+ DC in the presence of B infantis and B breve (data not shown). The proportion of DC expressing CD83 was also high in unstimulated cultures and there was a tendency for all bacterial strains to increase this proportion further, with L casei and L plantarum significantly increasing the level. CD86 was not significantly altered by any of the bacterial strains.

VSL#3 treatment of dendritic cells inhibits generation of Th1 cells

To determine whether the ability of VSL#3 or its components to increase IL-10 production by DC influenced the subsequent T cell response, two different assays were performed. Purified naïve CD4+ T cells were activated in the presence of enriched allogeneic DC treated with VSL#3, LPS, or medium alone and the cytokine profile of the differentiated T cells was examined. Enriched DC were potent stimulators of allogeneic naïve CD4+ T cells irrespective of pretreatment with bacterial products (data not shown). However, significantly fewer T cells committed to IFN-γ production were generated in cultures activated with VSL#3-treated DC (21.8 (SEM 5.0) %, n = 4) than in cultures stimulated with LPS treated DC (42.0 (SEM 4.1) %, n = 4) or unstimulated DC (36.3 (SEM 5.0) %, n = 4) (fig 7). The proportion of differentiated T cells making IL-10 or IL-4 did not differ significantly between the cultures. In addition, single probiotic strains were incubated with whole blood and the effect on IFN-γ production by CD8+ and CD8− T cells was assessed following polyclonal stimulation with PMA and ionomycin. Prior exposure to B longum and B infantis, but not the other bacteria tested, significantly reduced the proportion and absolute numbers of CD8+ T cells and CD8− T cells committed to IFN-γ production in a dose dependent manner (fig 8). Compared with medium control, the proportion of CD8− T cells producing IFN-γ was reduced by 46% with B longum (n = 9 independent experiments) and 62% with B infantis (n = 9 independent experiments); the proportion of CD8+ T cells producing IFN-γ was reduced by 50% (B longum) and 61% (B infantis). The effects of bacterial debris fractions on IFN-γ production were selective for cytokine production, rather than a reflection of reduced T cell activation or a toxic effect of the bacterial preparation.
as over 97% were activated (CD69+) by PMA and ionomycin irrespective of prior exposure to bacteria (data not shown). To assess whether the decrease in IFN-γ by T cells was dependent on IL-10, a neutralising anti-IL-10 antibody was added to some cultures. For both CD8+ and CD8– T cells, the inhibition of IFN-γ production by B longum was reversed significantly by a neutralising anti-IL-10 antibody, but not an isotype matched control. Anti-IL-10 reversed the inhibition of IFN-γ production by B infantis for CD8– T cells only. (fig 8).

**DISCUSSION**

The clinically active probiotic combination VSL#3 was a potent inducer of IL-10 by intestinal and blood DC and inhibited generation of proinflammatory Th1 cells. Individual strains within VSL#3 displayed distinct and diverse immunomodulatory effects. The most marked anti-inflammatory effect was shown by bifidobacterial species which upregulated IL-10 production by DC and decreased expression of the costimulatory molecules CD80 and CD40. These effects of probiotic bacteria on DC may underlie their anti-inflammatory activity.

The individual bacteria in VSL#3 displayed different effects on cytokine production by DC, arguing against a common bacterial component such as peptidoglycan mediating the effects. Differences between strains have been reported previously; B bifidum, B breve, and B infantis stimulated more IL-10 and less IL-12 and TNFα from a murine macrophage like cell line than B adolescentis. Moreover, there was no simple correlation between reported DC expression of TLR and responses to VSL#3. Thus responses of CD11c+ and CD11c– DC subsets to VSL#3 were broadly similar although these two populations express a different array of the known TLRs. The divergent patterns of responses to VSL#3 and expression of TLRs suggests that other receptors may be involved in DC recognition of VSL#3 or that recognition of VSL#3 components by TLRs on non-DC may contribute.

**Table 2** Effect of individual bacterial strains on costimulatory and maturation markers

<table>
<thead>
<tr>
<th>% Positive dendritic cells</th>
<th>CD80</th>
<th>CD40</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD11c+ DC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>13 (2)</td>
<td>35 (10)</td>
</tr>
<tr>
<td>L acidophilus</td>
<td>19 (10)</td>
<td>27 (8)</td>
</tr>
<tr>
<td>L casei</td>
<td>31 (8)</td>
<td>37 (7)</td>
</tr>
<tr>
<td>L plantarum</td>
<td>28 (9)</td>
<td>29 (5)</td>
</tr>
<tr>
<td>L bulgaricus</td>
<td>38 (13)</td>
<td>30 (6)</td>
</tr>
<tr>
<td>B longum</td>
<td>7 (5)</td>
<td>0 (0)*</td>
</tr>
<tr>
<td>B infantis</td>
<td>6 (4)*</td>
<td>3 (2)*</td>
</tr>
<tr>
<td>B breve</td>
<td>2 (1)*</td>
<td>0 (0)*</td>
</tr>
<tr>
<td>S thermophilus</td>
<td>23 (7)</td>
<td>18 (8)</td>
</tr>
<tr>
<td>S faecium</td>
<td>9 (6)</td>
<td>2 (1)*</td>
</tr>
<tr>
<td>E coli Nissle</td>
<td>26 (14)</td>
<td>13 (9)</td>
</tr>
<tr>
<td>LPS</td>
<td>13 (2)</td>
<td>43 (8)</td>
</tr>
</tbody>
</table>

Values shown as mean (SEM) (three to six independent experiments). *Significant difference between control and bacterial strain p<0.05.
Intestinal DC are functionally different from those at other sites. In vitro, VSL#3 increased the proportion not only of blood DC making IL-10 but also of colonic lamina propria DC making IL-10, suggesting that one mechanism of action of VSL#3 in vivo is to trigger DC production of anti-inflammatory IL-10 in intestinal mucosa. Patients with pouchitis taking VSL#3 have increased mucosal levels of IL-10 and decreased levels of IFN-γα and in murine colitis, proinflammatory TNF-α and IFN-γ are decreased following treatment with VSL#3. Enhanced production of IL-10 by DC may limit mucosal inflammation either by direct anti-inflammatory effects or by enhancing the generation or activity of regulatory T cells (Tr1). In experimental colitis, local administration of IL-10 in bacterial or viral vectorsameliorates inflammation. Adoptive transfer of regulatory T cells cures or prevents intestinal inflammation in murine colitis by IL-10 dependent mechanisms. In another mucosal environment in the lung, high concentrations of IL-10 produced by pulmonary DC are associated with the generation of regulatory T cells.

Bacteria may differentially alter antigen presentation and the level of DC activation. Bifidobacteria generally downregulated the proportion of DC expressing CD80 but not the proportion of those expressing CD86. This differential effect between members of the B7 family of costimulatory molecules may be related to the difference in proportions of DC expressing CD80 and CD86 in stimulated cultures. Confirming other work, we found more DC expressing CD86 than CD80 in the absence of stimulation. Thus, CD80 expression may be more readily modulated through environmental signals. Both CD80 and CD86 bind to CD28 and CD80 (CTLA4) on T cells. It remains controversial whether they have distinct functions, but relative amounts of CD80 and CD86 on antigen presenting cells may influence the type of T cell response generated.

Effects of bifidobacteria were not confined to CD80 and CD86. B breve and B infantis reduced the level of CD40 expression on DC. Signalling through CD40 increases IL-12 production by DC and enhances their survival. Increased levels of expression of CD40 on DCα and its ligand, CD154, on T cells in IBD tissue suggests that this interaction is important in mucosal inflammation. VSL#3 treatment of IBD may mediate downregulation of CD40 expression, breaking the inflammatory cycle of mutual T cell-DC stimulation.

In contrast to bifidobacteria, lactobacilli appeared to generate “semi-mature” DC, a phenotype characterised by increased costimulatory marker expression but low production of proinflammatory cytokines. Such “semi-mature” DC may contribute to the production of regulatory T cells and subsequent tolerance in vivo.

VSL#3 inhibited T cell production of IFN-γ in two different systems. This reduction in proinflammatory cytokine production was not accompanied by an obvious increase in either IL-4-producing or IL-10-producing T cells arguing against a...
simple model in which VSL#3 induces a switch from Th1 to Th2 production. On the basis of the current data, its is not possible to determine whether the effect of VSL#3 treated DC acts at the level of T cell instruction or whether it operates by selection and expansion of different T cell precursors. DC stimulated comparable proliferative responses irrespective of bacterial treatment, suggesting that a major effect on lymphocyte viability is unlikely. IL-10 may contribute to the effect on T cells because neutralising IL-10 partially reversed VSL#3 mediated downregulation of IFNγ.

In conclusion, VSL#3, which is clinically beneficial in the treatment of intestinal inflammation, changes the cytokines in DC from an inflammatory towards a regulatory profile, which may be instrumental in the immunomodulatory activity of probiotic treatments. An increased understanding of the effects of probiotic organisms on the immune system may enable refinement of probiotic treatments and enhance our knowledge of immune homeostasis in the specialised environment of the intestine.

ACKNOWLEDGEMENTS
This work was supported by grants from the Wellcome Trust and Medical Research Council (UK).

Authors’ affiliations
A L Hart, S C Knight, A J Stagg, Antigen Presentation Research Group, Imperial College London, Harrow, UK
K Lammers, F Rizzello, P Gionchetti, M Campieri, Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy
P Brigidi, B Vitali, Department of Pharmaceutical Sciences, University of Bologna, Bologna, Italy
M A Kamm, Department of Gastroenterology, St Mark’s Hospital, Harrow, UK

REFERENCES